# Eupraxia Pharmaceuticals Inc. (EPRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.40, market value $555 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Eupraxia Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.4×**. The shares trade at 5.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -6.7%** (5-yr avg -18.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -47.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -45.6%**. Each dollar of assets produces -45.6% of profit.

## Growth
- **EPS growth (1 yr): -45.8%**. Earnings per share fell 45.8%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.1×**. It would take 2.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 15.12** (quick 15.12). Current assets cover the next year's liabilities 15.12 times.
- **Altman Z-score: 59.43**. A Z-score of 59.43 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Eupraxia Pharmaceuticals Inc. does not currently pay a dividend, but it returned -20.3% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Eupraxia Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $16.35 (+95% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 56.7%** (YTD 11.3%, 3-mo 41.2%). The shares are up 56.7% over twelve months including dividends.
- **From 52-week high: -9.9%** (63.1% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 69**. An RSI of 69 is neutral.
- **Beta (1 yr): 1.50** (volatility 66%). Beta of 1.50 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EPRX · Page: https://foliofundamentals.com/stocks/eprx

Not investment advice.